Metabolic syndrome and non-alcoholic fatty liver disease: DIMALOE AND LUNAE

Scientific and Clinical Rationale

Metabolic Syndrome (MS) and non-alcoholic fatty liver disease (NAFLD/MASLD) recognize insulin resistance and silent low-grade chronic inflammation (Low Grade Chronic Inflammation - LGCI) as their two main pathophysiological drivers. Hypertrophic visceral adipose tissue releases an excess of free fatty acids and pro-inflammatory cytokines (such as TNF-α, IL-1, IL-6) into the portal circulation, which downstream block the insulin receptor at both the muscular and hepatic levels. This systemic and asymptomatic inflammatory state – or inflammaging – alters intestinal permeability, induces oxidative stress, and accelerates tissue deterioration (joint, vascular, and gastrointestinal), positioning itself as the true "mother of all" degenerative diseases.

The combined and synergistic approach with the nutraceuticals MOLTITUDO® DIAMLOE and MOLTITUDO® LUNAE precisely addresses this complex pathogenic network through a multi-target action. While DIAMLOE intervenes at the metabolic-cellular level, regulating glucose absorption, inhibiting de novo lipogenesis, and promoting appetite and body weight control, LUNAE acts complementarily by modulating the systemic and cellular inflammatory cascade through the blockade of 5-lipoxygenase (5-LOX) and the inhibition of the transcription factor NF-κB.

Both formulations in the MOLTITUDO® line are characterized by capsules and tablets that are entirely plant-based and suitable for those following a vegan diet, free from animal derivatives, naturally gluten-free, and sugar-free, ensuring maximum purity, tolerability, and cellular biocompatibility

PRODUCT_ITEM

Recommended Daily Dosage Schedule

In order to optimize the bioavailability of the phytocomplexes, modulate the postprandial glycemic response, and support inflammatory balance, the following intake is recommended:

• LUNCH:
• 2 capsules of MOLTITUDO® DIAMLOE (to be taken preferably 30 minutes before the meal)
• 1 tablet of MOLTITUDO® LUNAE (to be taken preferably with the meal)

PDF

• DINNER:
• 2 capsules of MOLTITUDO® DIAMLOE (to be taken preferably 30 minutes before the meal)
• 1 tablet of MOLTITUDO® LUNAE (to be taken preferably with the meal)

Take each dose with a glass of water.

Product Analysis and Rationale of Action

1. MOLTITUDO® DIAMLOE: Metabolic and Lipolytic Support and Appetite Control

• Rationale for use: It specifically acts on the modulation of lipid and carbohydrate metabolism. It reduces intestinal glucose absorption, hinders the conversion of carbohydrates into fatty acids (lipogenesis), and acts at the central level supporting the control of the feeling of satiety and mood, critical factors in patients with metabolic alterations. 

• Quantitative Composition per Daily Dose (4 capsules - 1800 mg):

Biological Mechanism of the Components of DIAMLOE:

• Garcinia cambogia (HCA 60%): Hydroxycitric acid competitively inhibits the hepatic enzyme ATP-citrate lyase, blocking the synthesis of fatty acids and cholesterol de novo. It increases hepatic glycogen synthesis and modulates serotonin, reducing compulsive appetite.
• Gymnema sylvestre (25% Gymnemic Acids): Gymnemic acids reduce intestinal glucose absorption by reversibly binding to intestinal receptors and exert a protective and supportive effect on pancreatic beta cells.
• Green Coffee (45% Chlorogenic Acid): Inhibits glucose-6-phosphatase and alpha-glucosidase, reducing hepatic glycogenolysis and intestinal glucose absorption, improving peripheral lipid utilization.
• Griffonia simplicifolia (20% 5-HTP): 5-hydroxytryptophan is the direct biological precursor of serotonin. It regulates mood and reduces complex carbohydrate cravings (craving).
• Maitake: Medicinal mushroom whose polysaccharides (beta-glucans) act by improving peripheral receptor sensitivity to insulin and supporting the immune system.
• Piperine (Piper longum): Acts as a bio-enlarger, inhibiting biotransformation enzymes (phase I and II) to significantly increase the bioavailability and half-life of all associated phytocomplexes.
• Dog Rose & Vitamin E: They provide a synergistic hydro- and lipophilic action for the protection of cell membranes from systemic oxidative stress.

2. MULTITUDO® LUNAE: Physiological Anti-inflammatory Modulation and Drainage

• Rationale for Use: Multi-level enzymatic and phytotherapeutic formulation aimed at extinguishing tissue- and intestinal low-grade chronic inflammation (LGCI), reducing localized tension states and oxidative damage. 

• Quantitative Composition per Daily Dose (2 tablets - 2000 mg):

Biological Mechanism of LUNAE Components:

• Bromelain (2500 GDU): A cysteine protease enzyme that reduces tissue edema, degrades extracellular fibrin deposits, and modulates the secretion of pro-inflammatory cytokines, also finding application in restoring gastrointestinal integrity.
• Boswellia serrata (65% Boswellic Acids): AKBA specifically inhibits the 5-lipoxygenase (5-LOX) enzyme, blocking the inflammatory leukotriene cascade without compromising the integrity of the gastric mucosa.
• Tetrahydrocurcuminoids: Active metabolites stably extracted from Curcuma longa, which interfere with the degradation of factor I$\kappa B$ by blocking the nuclear translocation of NF−$\kappa B$, suppressing the expression of COX−2, TNF−$\alpha$ and IL-6.

PLEASE NOTE: The information presented in the product sheets on this site is for exclusively informative and educational purposes and does not represent medical advice. The published contents are not intended to replace the relationship with a doctor or any medical indications, diagnoses, or prescriptions. The reported information describes the ingredients and characteristics of food supplements, designed as support for the balance and well-being of the organism within a healthy lifestyle. Food supplements are not medicines and must not be used to prevent, diagnose, treat, or alleviate diseases or pathological conditions.

Bibliographic References and Clinical Studies

Studies on Metabolism, Obesity and Glycemic Control (DIAMLOE)

Heymsfield SB, et al. Garcinia cambogia (hydroxycitric acid) in weight loss: a randomized controlled trial. JAMA. 1998;280:1596–1600.

Onakpoya I, et al. The use of Garcinia extract (Hydroxycitric Acid) as a weight reduction supplement: a systematic review and meta-analysis of randomized clinical trials. J Obes. 2011;509038.

Baskaran K, et al. Antidiabetic effect of a leaf extract from Gymnema sylvestre in non-insulin-dependent diabetes mellitus patients. J Ethnopharmacol. 1990;30:295–300.

Vinson JA, et al. Randomized, double-blind, placebo-controlled, linear dose, crossover study to evaluate the efficacy and safety of a green coffee bean extract in overweight subjects. Diabetes Metab Syndr Obes. 2012;5:21–27.

Cangiano C, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr. 1992;56:863–867.

Kubo K, et al. Anti-diabetic activity of Maitake mushrooms (Grifola frondosa). J Nutr. 1994.

Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. 2007;47:735–748.

Studies on Chronic Inflammation, Edema and Pain (LUNAE)

de Souza GM, et al. Is bromelain effective in controlling pain, edema, and trismus after lower third molar surgery? A systematic review and meta-analysis. Phytother Res. 2019;33(3):473–481.

Varilla V, et al. Bromelain: a review of its anti-inflammatory properties and clinical applications. Evid Based Complement Alternat Med. 2021.

Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 2006;72(12):1100–1116.

Kimmatkar N, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee--a randomized double blind placebo controlled trial. Phytomedicine. 2003;10(1):3–7.

Aggarwal BB, et al. Pharmacological basis of curcumin in chronic diseases. Trends Pharmacol Sci. 2009;30:85–94.

Panahi Y, et al. Curcuminoids in osteoarthritis: a systematic review and meta-analysis. J Diet Suppl. 2016;13(2):209–220.